Off-Patent Industry Uproar On Two Acts Potentially Harming Generics And Biosimilars
The PREVAIL and PERA Acts Were Introduced By The Senate In 2023
While senator Coons ensured that the PREVAIL and PERA Acts would not “reverse” already achieved work on drug price reductions, industry players oppose the bipartisan bills, pushing the Senate to vote no.
